Recensione

Bibliografia__________________________________________________________________________

Garre, A., Piquero, J., Trullas, C., & Martinez, G. (2018). Efficacy and safety of a new topical hair loss-Lotion containing oleanoli c acid, apigenin, biotinyl tripeptide-1, diaminopyrimidine oxide, adenosine, biotin and ginkgo biloba in patients with androgenetic alopecia and telogen effluvium: a six-month open-label prospective clinical study. J Cosmo Trichol, 4(1000132), 2.

Abstract. In this study, minoxidil, which is well known as a pharmaceutical raw material, and diaminopyrimidine oxide (DAO), which is a cosmetic raw material, were used as active ingredients to evaluate the physical properties of niosomes and compare the skin penetrations of artificial skin. To prepare niosomes of the size of nanoparticles, a high pressure homogenization method was used, and physical properties were evaluated with a zetasizer. The particle size of the noisome including the active ingredient was measured to be 99 to 123 nm according to HLB, and the zeta potential was measured in the range of -60 to -81 mV. Through DSC (differential scanning colorimetry), it was confirmed that minoxidil, a crystalline component, was uniformly dissolved in an amorphous state in niosomes. In order to confirm and compare skin penetration, it was measured by the in vitro Franz diffusion cell method, and the niosome formulation showed 3.4 times higher penetration for minoxidil and 11.1 times higher penetration for DAO than the control gel formulation. In addition, when comparing the skin penetration of minoxidil niosome and DAO niosome, a similar trend was shown, and the penetration amount of DAO was relatively high. The shapes of the niosome formulations with different HLB values were observed using Cryo-TEM, and it was confirmed that vesicles were formed in all of them and that they were intermediate between SUV (small unilamella vesicle) and LUV (large unilamella vesicle). Through this study, minoxidil, an effective drug for hair loss, and DAO, a cosmetic raw material, can be effectively delivered to the skin by encapsulating them in a noisome formulation.

Vincenzi, C., Marisaldi, B., Tosti, A., & Patel, B. (2019). Effects of a new topical treatment containing several hair growth promoters in women with early female pattern hair loss. Skin appendage disorders, 5(3), 146-151.

Abstract. Background: Female pattern hair loss (FPHL) is increasing ly common and often presents with hair shedding. Spec tral.DNC-N® contains anti-inflammatory actives and hair growth promoters. Objectives: To assess the efficacy and tolerability of Spectral DNC-N® (DS Laboratories, Inc.) in women with early FPHL and excessive shedding. Methods: Forty-nine patients were treated with Spectral DNC-N®, applied twice daily for 3 months; 28 patients were included in the 3-month treatment extension. Efficacy assessments included the degree of hair shedding using the validated hair shedding visual scale, hair mass index (HMI), and photographic evaluation. Results: There was a statistically significant decrease in hair shedding and a corresponding increase in HMI by month 3, which was maintained through month 6. The mean investigator-assessed hair shedding score decreased from 3.5 to 2.0 and the hair mass increased from 75.8 to 84.3 mm2/cm2 by month 3 (both p < 0.01 compared with baseline). By month 6, the hair shedding score was reduced to 1.6 and the hair mass was maintained. Most patients (75%) showed an increase in global hair density. Conclusions: Spectral.DNC-N® significantly reduced hair shedding, with a corresponding increase in hair mass and density. These effects were already evident after 3 months’ treatment and further improved in those patients who continued treatment to month 6. Tolerability was good and patient satisfaction levels were high.

Loing, E., Lachance, R., Ollier, V., & Hocquaux, M. (2013). A new strategy to modulate alopecia using a combination of two specific and unique ingredients. J Cosmet Sci, 64(1), 45-58.

Synopsis. Male pattern hair loss is a major cosmetic concern affecting both genders with a preference for men. Major causes of hair loss in genetically predisposed individuals include hormonal dysfunction, loss of extracellular matrix (ECM) proteins in the follicular bed, and localized microinfl ammation. Few options are yet available to correct the problem. For this purpose, a cosmetic active ingredient was developed by combining a Trifolium pratense fl ower extract and a biomimetic peptide and tested clinically for the prevention of hair loss. Thirty volunteers with recessing hair were recruited for this randomized, placebo-controlled study. Clinical effi cacy, following daily topical application of the mixture to the scalp, was checked using TrichoScan™ for the measurement of human hair. Within 4 months of application, anagen hair increased at an average by +13%, telogen hair density decreased by −29%, and the anagen/telogen (A/T) ratio increased by +46% over baseline in the treated group. Results strongly differed from those of the placebo group (anagen, −2%; telogen, +23%; A/T ratio, −33%). Investigation of the potential mechanisms involved in the positive effects of the test product on hair growth pointed at inhibition of 5-α-reductase activity, reduction of infl ammatory reactions, and stimulation of ECM protein synthesis in the vicinity of the hair follicle.

Qiu, S., Pan, Z., Jiang, X., Lv, G., Feng, A., & Chen, H. (2024). The synergistic effect of phototherapy and active substances on hair growth. Journal of Photochemistry and Photobiology B: Biology, 259, 113008.

Abstract. Androgenic alopecia (AGA) typically manifests post-puberty, resulting in decreases in hair density, disruptions in the hair growth cycle, and alterations in hair follicle micro structure. Dihydrotestosterone (DHT) is a key hormone implicated in hair loss, especially on male. In this study, we found that each of arginine (Arg), arterial extract (AE) or biotin tripeptide-1 (BT-1), when combined with low level light therapy (LLLT, at 630 nm, 2 J/cm2), showed the efficacy in enhancing mitochondrial functions, cell proliferation and collagen synthesis in fibroblasts. Additionally, CARRIPOWER (the complexes of AE, BT-1, Arg, and Diaminopyrimidine derivatives), in conjunction with LLLT (630 nm, 2 J/cm2), showed promising results in dermal papilla cells (DPCs). The promising results contained not also inflammatory cytokines (IL-1β and IL-6) and cell pro apoptotic factor (TGF-β2) reduction, but also Wnt pathway inhibition by decreasing DKK1 level, and pro-hair growth factors (vascular endothelial growth factor (VEGF) and β-catenin) increase. This innovative combination therapy offers a potential solution for the treatment of AGA, addressing both hormonal and cellular factors involved in hair loss.